Importance of atypical pathogens of community-acquired pneumonia

Clinical Infectious Diseases

Volumn 31, Issue SUPPL. 2, 2000, Pages

  Plouffe, J F ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL FEATURE; CONFERENCE PAPER; HUMAN; LEGIONELLA; LEGIONNAIRE DISEASE; MYCOPLASMA PNEUMONIAE; PNEUMONIA; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY-ACQUIRED INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; LEGIONNAIRES' DISEASE; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA;

EID: 0034453190     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/314058     Document Type: Conference Paper

References (40)

1. Value of noninvasive studies in community-acquired pneumonia
2. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia
3. The epidemiology of community-acquired pneumonia among hospitalized adults
4. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course
5. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin
6. Aetiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital
7. Processes and outcomes of care for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study
8. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
9. An acute infection of the respiratory tract with atypical pneumonia
10. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections
11. Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population
12. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
13. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features
14. Comparative clinical and laboratory features of Legionella with pneumococcal and mycoplasma pneumonias
15. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen
16. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection
17. Sporadic legionellosis in the United States: The first thousand cases
18. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: Similarities and differences on presentation
19. Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis
20. Clinical diagnosis of Legionnaires' disease (LD) using a multivariate model
21. Reevaluation of the definition of Legionnaires' disease: Use of the urinary antigen assay
22. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one-year prospective study of 346 consecutive patients
23. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland
24. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality
25. Implications for macrolide treatment in community-acquired pneumonia
26. Empirical therapy for nonhospitalized patients with community-acquired pneumonia
27. Associations between antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
28. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
29. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds
30. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY antimicrobial surveillance program
31. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract
32. Empirical therapy of community-acquired pneumonia: Macrolides are not ideal choices
33. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens: Findings of the Alexander Project 1992-1996
34. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae
35. In vitro activity of a new quinolone, gatifloxacin, against Chlamydia pneumoniae and Chlamydia trachomatis
36. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species
37. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)
38. Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season
39. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 Results from the SENTRY antimicrobial surveillance program
40. Community-acquired pneumonia in adults: Guidelines for management